Skip to content
2000
image of The Impact of Non-Steroidal Anti-Inflammatory Drugs on Gastrointestinal Bleeding: Review on Risk Scoring for Better Prediction

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for pain relief and inflammation management; however, they can lead to serious upper gastrointestinal (GI) issues, including ulcers, bleeding, and perforations. This review explores various risk factors for NSAID-related GI complications, including medication dosage, duration of treatment, patient age, health history, and interactions with other drugs. It also evaluates existing measures to reduce these risks, such as using proton pump inhibitors (PPIs) and selective COX-2 inhibitors, while discussing their limitations. Emphasis is placed on the value of prediction tools that integrate multiple risk factors to enhance preventive care. The review provides an in-depth analysis of current scoring systems and examines future directions, including the integration of biomarkers, genetic data, and technologies like machine learning to improve prediction and clinical utility. By addressing gaps in existing models, it offers insights into advancing personalized approaches to minimize NSAID-induced GI complications.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863356598250523095124
2025-06-11
2025-09-14

  • From This Site

    /content/journals/cds/10.2174/0115748863356598250523095124
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Fosbøl E.L. Gislason G.H. Jacobsen S. Abildstrom S.Z. Hansen M.L. Schramm T.K. Folke F. Sørensen R. Rasmussen J.N. Køber L. Madsen M. Torp-Pedersen C. The pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) from 1997 to 2005: A nationwide study on 4.6 million people. Pharmacoepidemiol. Drug Saf. 2008 17 8 822 833 10.1002/pds.1592 18383428
    [Google Scholar]
  2. Conaghan P.G. A turbulent decade for NSAIDs: Update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol. Int. 2012 32 6 1491 1502 10.1007/s00296‑011‑2263‑6 22193214
    [Google Scholar]
  3. Salles-Montaudon N. Fourrier A. Dartigues J.F. Rainfray M. Emeriau J.P. Evolution of drug treatments for elderly people living at home. Rev. Med. Interne 2000 21 8 664 671 10.1016/S0248‑8663(00)80021‑1 10989491
    [Google Scholar]
  4. Flugsrud G. Nordsletten L. Reinholt F. Risberg M. Rydevik K. Uhlig T. Artrose. Tidsskr. Nor. Laegeforen. 2010 130 21 2136 2140 10.4045/tidsskr.09.1054 21052117
    [Google Scholar]
  5. Bindu S. Mazumder S. Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem. Pharmacol. 2020 180 114147 10.1016/j.bcp.2020.114147 32653589
    [Google Scholar]
  6. Sohail R. Mathew M. Patel K.K. Reddy S.A. Haider Z. Naria M. Habib A. Abdin Z.U. Razzaq Chaudhry W. Akbar A. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) and gastroprotective NSAIDs on the gastrointestinal tract: A narrative review. Cureus 2023 15 4 e37080 10.7759/cureus.37080 37153279
    [Google Scholar]
  7. Kim S.H. Yun J.M. Chang C.B. Piao H. Yu S.J. Shin D.W. Prevalence of upper gastrointestinal bleeding risk factors among the general population and osteoarthritis patients. World J. Gastroenterol. 2016 22 48 10643 10652 10.3748/wjg.v22.i48.10643 28082817
    [Google Scholar]
  8. Gómez-Acebo I. Dierssen-Sotos T. de Pedro M. Pérez-Gómez B. Castaño-Vinyals G. Fernández-Villa T. Palazuelos-Calderón C. Amiano P. Etxeberria J. Benavente Y. Fernández-Tardón G. Salcedo-Bellido I. Capelo R. Peiró R. Marcos-Gragera R. Huerta J.M. Tardón A. Barricarte A. Altzibar J.M. Alonso-Molero J. Dávila-Batista V. Aragonés N. Pollán M. Kogevinas M. Llorca J. Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. BMC Public Health 2018 18 1 1134 10.1186/s12889‑018‑6019‑z 30241493
    [Google Scholar]
  9. Griffin M.R. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am. J. Med. 1998 104 3 23S 29S 10.1016/S0002‑9343(97)00207‑6 9572317
    [Google Scholar]
  10. Haghbin H. Zakirkhodjaev N. Husain F.F. Lee-Smith W. Aziz M. Risk of gastrointestinal bleeding with concurrent use of NSAID and SSRI: A systematic review and network meta-analysis. Dig. Dis. Sci. 2023 68 5 1975 1982 10.1007/s10620‑022‑07788‑y 36526813
    [Google Scholar]
  11. Bedene A. van Dorp E.L.A. Rosendaal F.R. Dahan A. Lijfering W.M. Risk of drug-related upper gastrointestinal bleeding in the total population of the Netherlands: A time-trend analysis. BMJ Open Gastroenterol. 2022 9 1 e000733 10.1136/bmjgast‑2021‑000733 35012975
    [Google Scholar]
  12. Castellana C. Pecere S. Furnari M. Telese A. Matteo M.V. Haidry R. Eusebi L.H. Side effects of long-term use of proton pump inhibitors: Practical considerations. Pol. Arch. Intern. Med. 2021 131 6 541 549 10.20452/pamw.15997 33982542
    [Google Scholar]
  13. Tielleman T. Bujanda D. Cryer B. Epidemiology and risk factors for upper gastrointestinal bleeding. Gastrointest. Endosc. Clin. N. Am. 2015 25 3 415 428 10.1016/j.giec.2015.02.010 26142028
    [Google Scholar]
  14. Costable N.J. Greenwald D.A. Upper gastrointestinal bleeding. Clin. Geriatr. Med. 2021 37 1 155 172 10.1016/j.cger.2020.09.001 33213769
    [Google Scholar]
  15. Theken K.N. Lee C.R. Gong L. Caudle K.E. Formea C.M. Gaedigk A. Klein T.E. Agúndez J.A.G. Grosser T. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti‐inflammatory drugs. Clin. Pharmacol. Ther. 2020 108 2 191 200 10.1002/cpt.1830 32189324
    [Google Scholar]
  16. Chi T.Y. Zhu H.M. Zhang M. Risk factors associated with nonsteroidal anti-inflammatory drugs (NSAIDs)-induced gastrointestinal bleeding resulting on people over 60 years old in Beijing. Medicine 2018 97 18 e0665 10.1097/MD.0000000000010665 29718891
    [Google Scholar]
  17. Tai F.W.D. McAlindon M.E. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin. Med. 2021 21 2 131 134 10.7861/clinmed.2021‑0039 33762373
    [Google Scholar]
  18. Verhaegh B.P.M. de Vries F. Masclee A.A.M. Keshavarzian A. de Boer A. Souverein P.C. Pierik M.J. Jonkers D.M.A.E. High risk of drug‐induced microscopic colitis with concomitant use of NSAID s and proton pump inhibitors. Aliment. Pharmacol. Ther. 2016 43 9 1004 1013 10.1111/apt.13583 26956016
    [Google Scholar]
  19. Zhang X. Xiao X. Chen P.R. Li Y.N. Lv X.H. Yang J.L. Proton pump inhibitors increase the risk of nonsteroidal anti-inflammatory drug-related small-bowel injury: A systematic review with meta-analysis. Clin. Transl. Gastroenterol. 2023 14 6 e00588 10.14309/ctg.0000000000000588 37019683
    [Google Scholar]
  20. Wang B. Wu L. Chen J. Dong L. Chen C. Wen Z. Hu J. Fleming I. Wang D.W. Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets. Signal Transduct. Target. Ther. 2021 6 1 94 10.1038/s41392‑020‑00443‑w 33637672
    [Google Scholar]
  21. Adelizzi R.A. COX-1 and COX-2 in health and disease. J. Am. Osteopath. Assoc. 1999 99 11_suppl S7 10.7556/jaoa.1999.99.11.S7
    [Google Scholar]
  22. Cryer B. Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 1998 104 5 413 421 10.1016/S0002‑9343(98)00091‑6 9626023
    [Google Scholar]
  23. Desborough M.J.R. Keeling D.M. The aspirin story – From willow to wonder drug. Br. J. Haematol. 2017 177 5 674 683 10.1111/bjh.14520 28106908
    [Google Scholar]
  24. Hunter T.S. Robison C. Gerbino P.P. Emerging evidence in NSAID pharmacology: Important considerations for product selection. Am. J. Manag. Care 2015 21 7 Suppl. S139 S147 26168321
    [Google Scholar]
  25. McGettigan P. Henry D. Current problems with non-specific COX inhibitors. Curr. Pharm. Des. 2000 6 17 1693 1724 10.2174/1381612003398690 11102559
    [Google Scholar]
  26. Wright J.M. The double-edged sword of COX-2 selective NSAIDs. CMAJ 2002 167 10 1131 1137 12427705
    [Google Scholar]
  27. Stiller C.O. Hjemdahl P. Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials. J. Intern. Med. 2022 292 4 557 574 10.1111/joim.13505 35585779
    [Google Scholar]
  28. Warner T.D. Giuliano F. Vojnovic I. Bukasa A. Mitchell J.A. Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 1999 96 13 7563 7568 10.1073/pnas.96.13.7563 10377455
    [Google Scholar]
  29. Howes L.G. Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther. Clin. Risk Manag. 2007 3 5 831 845 18473007
    [Google Scholar]
  30. Antman E.M. DeMets D. Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005 112 5 759 770 10.1161/CIRCULATIONAHA.105.568451 16061757
    [Google Scholar]
  31. Khan S. Andrews K.L. Chin-Dusting J.P.F. Cyclo-oxygenase (COX) inhibitors and cardiovascular risk: Are non-steroidal anti-inflammatory drugs really anti-inflammatory? Int. J. Mol. Sci. 2019 20 17 4262 10.3390/ijms20174262 31480335
    [Google Scholar]
  32. Bonnesen K. Schmidt M. Recategorization of non-aspirin nonsteroidal anti-inflammatory drugs according to clinical relevance: Abandoning the traditional nsaid terminology. Can. J. Cardiol. 2021 37 11 1705 1707 10.1016/j.cjca.2021.06.014 34182020
    [Google Scholar]
  33. Borer J.S. Simon L.S. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: Achieving a balance. Arthritis Res. Ther. 2005 7 Suppl 4 Suppl. 4 S14 S22 10.1186/ar1794 16168077
    [Google Scholar]
  34. Drożdżal S. Lechowicz K. Szostak B. Rosik J. Kotfis K. Machoy-Mokrzyńska A. Białecka M. Ciechanowski K. Gawrońska-Szklarz B. Kidney damage from nonsteroidal anti‐inflammatory drugs—Myth or truth? Review of selected literature. Pharmacol. Res. Perspect. 2021 9 4 e00817 10.1002/prp2.817 34310861
    [Google Scholar]
  35. Bruno A. Tacconelli S. Contursi A. Ballerini P. Patrignani P. Cyclooxygenases and platelet functions. Adv. Pharmacol. 2023 97 133 165 10.1016/bs.apha.2022.12.001 37236757
    [Google Scholar]
  36. Cofer L.B. Barrett T.J. Berger J.S. Aspirin for the primary prevention of cardiovascular disease: Time for a platelet-guided approach. Arterioscler. Thromb. Vasc. Biol. 2022 42 10 1207 1216 10.1161/ATVBAHA.122.318020 36047408
    [Google Scholar]
  37. Undas A. Brummel-Ziedins K.E. Mann K.G. Antithrombotic properties of aspirin and resistance to aspirin: Beyond strictly antiplatelet actions. Blood 2007 109 6 2285 2292 10.1182/blood‑2006‑01‑010645 17148593
    [Google Scholar]
  38. Funk C.D. FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. J. Cardiovasc. Pharmacol. 2007 50 5 470 479 10.1097/FJC.0b013e318157f72d 18030055
    [Google Scholar]
  39. Becker R.C. COX-2 inhibitors. Tex. Heart Inst. J. 2005 32 3 380 383 16392224
    [Google Scholar]
  40. Jaul E. Barron J. Age-related diseases and clinical and public health implications for the 85 years old and over population. Front. Public Health 2017 5 335 10.3389/fpubh.2017.00335 29312916
    [Google Scholar]
  41. Benetos A. Petrovic M. Strandberg T. Hypertension management in older and frail older patients. Circ. Res. 2019 124 7 1045 1060 10.1161/CIRCRESAHA.118.313236 30920928
    [Google Scholar]
  42. Ibarz M. Haas L.E.M. Ceccato A. Artigas A. The critically ill older patient with sepsis: A narrative review. Ann. Intensive Care 2024 14 1 6 10.1186/s13613‑023‑01233‑7 38200360
    [Google Scholar]
  43. Lanza F.L. Chan F.K.L. Quigley E.M.M. Practice Parameters Committee of the American College of Gastroenterology Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009 104 3 728 738 10.1038/ajg.2009.115 19240698
    [Google Scholar]
  44. Kamada T. Satoh K. Itoh T. Ito M. Iwamoto J. Okimoto T. Kanno T. Sugimoto M. Chiba T. Nomura S. Mieda M. Hiraishi H. Yoshino J. Takagi A. Watanabe S. Koike K. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J. Gastroenterol. 2021 56 4 303 322 10.1007/s00535‑021‑01769‑0 33620586
    [Google Scholar]
  45. Joo M.K. Park C.H. Kim J.S. Park J.M. Ahn J.Y. Lee B.E. Clinical guidelines for drug-related peptic ulcer, 2020 revised edition. Gut Liver 2020 14 6 707 726 10.5009/gnl20246
    [Google Scholar]
  46. Kim J. Lee J. Shin C.M. Lee D.H. Park B.J. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res. Care 2015 3 1 e000133 10.1136/bmjdrc‑2015‑000133 26719806
    [Google Scholar]
  47. Kang D.O. An H. Park G.U. Yum Y. Park E.J. Park Y. Jang W.Y. Kim W. Choi J.Y. Roh S.Y. Na J.O. Kim J.W. Kim E.J. Rha S.W. Park C.G. Seo H.S. Choi C.U. Cardiovascular and bleeding risks associated with nonsteroidal anti-inflammatory drugs after myocardial infarction. J. Am. Coll. Cardiol. 2020 76 5 518 529 10.1016/j.jacc.2020.06.017 32731930
    [Google Scholar]
  48. Venerito M. Wex T. Malfertheiner P. Nonsteroidal anti-inflammatory drug-induced gastroduodenal bleeding: Risk factors and prevention strategies. Pharmaceuticals 2010 3 7 2225 2237 10.3390/ph3072225 27713351
    [Google Scholar]
  49. Lin K.J. De Caterina R. Rodríguez L.A.G. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: A population-based, nested case-control study. Circ. Cardiovasc. Qual. Outcomes 2014 7 1 70 77 10.1161/CIRCOUTCOMES.113.000494 24254886
    [Google Scholar]
  50. Bazzoli F. De Luca L. Graham D.Y. Helicobacter pylori infection and the use of NSAIDs. Best Pract. Res. Clin. Gastroenterol. 2001 15 5 775 785 10.1053/bega.2001.0234 11566040
    [Google Scholar]
  51. van de Laar M.A.F.J. Schöfl R. Prevoo M. Jastorff J. Predictive value of gastrointestinal symptoms and patient risk factors for NSAID-associated gastrointestinal ulcers defined by endoscopy? Insights from a pooled analysis of two naproxen clinical trials. PLoS One 2023 18 4 e0284358 10.1371/journal.pone.0284358 37053160
    [Google Scholar]
  52. Lanas A. Chan F.K.L. Peptic ulcer disease. Lancet 2017 390 10094 613 624 10.1016/S0140‑6736(16)32404‑7 28242110
    [Google Scholar]
  53. Fries J.F. Williams C.A. Bloch D.A. Michel B.A. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am. J. Med. 1991 91 3 213 222 10.1016/0002‑9343(91)90118‑H 1892140
    [Google Scholar]
  54. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am. J. Med. 1998 105 1 31S 38S 10.1016/S0002‑9343(98)00072‑2 9715832
    [Google Scholar]
  55. Lee S. Heo K.N. Lee M.Y. Ah Y.M. Shin J. Lee J.Y. Derivation and validation of a risk prediction score for nonsteroidal anti‐inflammatory drug‐related serious gastrointestinal complications in the elderly. Br. J. Clin. Pharmacol. 2023 89 7 2216 2223 10.1111/bcp.15696 36807272
    [Google Scholar]
  56. Cheetham T.C. Levy G. Spence M. Predicting the risk of gastrointestinal bleeding due to nonsteroidal antiinflammatory drugs: NSAID electronic assessment of risk. J. Rheumatol. 2003 30 10 2241 2244 14528523
    [Google Scholar]
  57. Tangkiatkumjai M. Vadcharavivad S. Mahachai V. Prediction of UGIB event in NSAID users: A model development. J. Med. Assoc. Thai. 2005 88 5 672 677 16149687
    [Google Scholar]
  58. de Groot N.L. Hagenaars M.P. Smeets H.M. Steyerberg E.W. Siersema P.D. van Oijen M.G.H. Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: Development and validation of risk scores for either medication in two large Dutch cohorts. J. Gastroenterol. 2014 49 2 245 253 10.1007/s00535‑013‑0817‑y 23609946
    [Google Scholar]
  59. Martínez C. Blanco G. Ladero J.M. García-Martín E. Taxonera C. Gamito F.G. Diaz-Rubio M. Agúndez J.A.G. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol. 2004 141 2 205 208 10.1038/sj.bjp.0705623 14707031
    [Google Scholar]
  60. Bowalgaha K. Elliot D.J. Mackenzie P.I. Knights K.M. Swedmark S. Miners J.O. S‐Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP‐glucuronosyltransferases (UGT): Role of UGT2B7 in the elimination of naproxen. Br. J. Clin. Pharmacol. 2005 60 4 423 433 10.1111/j.1365‑2125.2005.02446.x 16187975
    [Google Scholar]
  61. Zobdeh F. Eremenko I.I. Akan M.A. Tarasov V.V. Chubarev V.N. Schiöth H.B. Mwinyi J. Pharmacogenetics and pain treatment with a focus on non-steroidal anti-inflammatory drugs (NSAIDs) and antidepressants: A systematic review. Pharmaceutics 2022 14 6 1190 10.3390/pharmaceutics14061190 35745763
    [Google Scholar]
  62. Forgerini M. Urbano G. Nadai T.R. Batah S.S. Fabro A.T. Mastroianni P.C. Genetic variants in PTGS1 and NOS3 genes increase the risk of upper gastrointestinal bleeding: A case–control study. Front. Pharmacol. 2021 12 671835 10.3389/fphar.2021.671835 34290607
    [Google Scholar]
  63. Mallah N. Zapata-Cachafeiro M. Aguirre C. Ibarra-García E. Palacios-Zabalza I. Macías-García F. Domínguez-Muñoz J.E. Piñeiro-Lamas M. Ibáñez L. Vidal X. Vendrell L. Martin-Arias L. Sáinz-Gil M. Velasco-González V. Figueiras A. Corrigendum: Influence of polymorphisms involved in platelet activation and inflammatory response on aspirin-related upper gastrointestinal bleeding: A case-control study. Front. Pharmacol. 2020 11 1072 10.3389/fphar.2020.01072 32765275
    [Google Scholar]
  64. Cho J.H. Choi J.S. Chun S.W. Lee S. Han K.J. Kim H.M. The IL-1B genetic polymorphism is associated with aspirin-induced pepticulcers in a korean ethnic group. Gut Liver 2016 10 3 362 368 10.5009/gnl15129 26601827
    [Google Scholar]
  65. Forgerini M. Zanelli C.F. Valentini S.R. Mastroianni P.C. Influence of IL-β, IL-1RN, and TNF-α variants on the risk of acetylsalicylic acid-induced upper gastrointestinal bleeding: A case-control study. Einstein 2024 22 eAO0746 10.31744/einstein_journal/2024AO0746 39194098
    [Google Scholar]
  66. Figueiras A. Estany-Gestal A. Aguirre C. Ruiz B. Vidal X. Carvajal A. Salado I. Salgado-Barreira A. Rodella L. Moretti U. Ibáñez L. EMPHOGEN group CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding. Pharmacogenet. Genomics 2016 26 2 66 73 10.1097/FPC.0000000000000186 26544900
    [Google Scholar]
  67. Rafanan B.S. Jr Valdecañas B.F. Lim B.P. Malairungsakul A. Tassanawipas W. Shiyi C. Tse L.F. Luong T.K. Consensus recommendations for managing osteoarthritic pain with topical NSAIDs in Asia-Pacific. Pain Manag. 2018 8 2 115 128 10.2217/pmt‑2017‑0047 29251544
    [Google Scholar]
  68. Yang M. He M. Zhao M. Zou B. Liu J. Luo L.M. Li Q.L. He J.H. Lei P.G. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: A systematic review. Curr. Med. Res. Opin. 2017 33 6 973 980 10.1080/03007995.2017.1281110 28076696
    [Google Scholar]
  69. Gwee K.A. Goh V. Lima G. Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J. Pain Res. 2018 11 361 374 10.2147/JPR.S156938 29491719
    [Google Scholar]
  70. Lin X.H. Young S.H. Luo J.C. Peng Y.L. Chen P.H. Lin C.C. Chen W.M. Hou M.C. Lee F.Y. Risk factors for upper gastrointestinal bleeding in patients taking selective COX-2 inhibitors: A nationwide population-based cohort study. Pain Med. 2018 19 2 225 231 10.1093/pm/pnx097 28460044
    [Google Scholar]
  71. Kim T.J. Kim E.R. Hong S.N. Kim Y.H. Lee Y.C. Kim H.S. Kim K. Chang D.K. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci. Rep. 2019 9 1 11696 10.1038/s41598‑019‑48173‑6 31406189
    [Google Scholar]
  72. Silverstein F.E. Faich G. Goldstein J.L. Simon L.S. Pincus T. Whelton A. Makuch R. Eisen G. Agrawal N.M. Stenson W.F. Burr A.M. Zhao W.W. Kent J.D. Lefkowith J.B. Verburg K.M. Geis G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000 284 10 1247 1255 10.1001/jama.284.10.1247 10979111
    [Google Scholar]
  73. Farzaei M.H. Abdollahi M. Rahimi R. Role of dietary polyphenols in the management of peptic ulcer. World J. Gastroenterol. 2015 21 21 6499 6517 10.3748/wjg.v21.i21.6499 26074689
    [Google Scholar]
  74. Chiu H.F. Venkatakrishnan K. Golovinskaia O. Wang C.K. Gastroprotective effects of polyphenols against various gastro-intestinal disorders: A mini-review with special focus on clinical evidence. Molecules 2021 26 7 2090 10.3390/molecules26072090 33917379
    [Google Scholar]
  75. Strate L.L. Singh P. Boylan M.R. Piawah S. Cao Y. Chan A.T. A prospective study of alcohol consumption and smoking and the risk of major gastrointestinal bleeding in men. PLoS One 2016 11 11 e0165278 10.1371/journal.pone.0165278 27824864
    [Google Scholar]
  76. Samaneh S. Zhila T. Saeid E. Elham M.A. Ali K. Faroughi F. 44395A case-control study on the risk of upper gastrointestinal bleeding in patients taking non-steroidal anti-inflammataory drugs (NSAIDs) in Mashhad, IranSajjadi. Asian J. Res. Rep. Gastroenterol. 2018 1 13 21
    [Google Scholar]
  77. Thomas K.S. Muir K.R. Doherty M. Jones A.C. O’Reilly S.C. Bassey E.J. Home based exercise programme for knee pain and knee osteoarthritis: Randomised controlled trial. BMJ 2002 325 7367 752 10.1136/bmj.325.7367.752 12364304
    [Google Scholar]
  78. Deyle G.D. Allison S.C. Matekel R.L. Ryder M.G. Stang J.M. Gohdes D.D. Hutton J.P. Henderson N.E. Garber M.B. Physical therapy treatment effectiveness for osteoarthritis of the knee: A randomized comparison of supervised clinical exercise and manual therapy procedures versus a home exercise program. Phys. Ther. 2005 85 12 1301 1317 10.1093/ptj/85.12.1301 16305269
    [Google Scholar]
  79. Otani K. Tanigawa T. Watanabe T. Shimada S. Nadatani Y. Nagami Y. Tanaka F. Kamata N. Yamagami H. Shiba M. Tominaga K. Fujiwara Y. Arakawa T. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion 2017 95 1 22 28 10.1159/000452356 28052268
    [Google Scholar]
  80. Monteros M.J.M. Galdeano C.M. Balcells M.F. Weill R. De Paula J.A. Perdigón G. Cazorla S.I. Probiotic lactobacilli as a promising strategy to ameliorate disorders associated with intestinal inflammation induced by a non-steroidal anti-inflammatory drug. Sci. Rep. 2021 11 1 571 10.1038/s41598‑020‑80482‑z 33436961
    [Google Scholar]
  81. Bozomitu L. Miron I. Adam Raileanu A. Lupu A. Paduraru G. Marcu F.M. Buga A.M.L. Rusu D.C. Dragan F. Lupu V.V. The gut microbiome and its implication in the mucosal digestive disorders. Biomedicines 2022 10 12 3117 10.3390/biomedicines10123117 36551874
    [Google Scholar]
  82. Guo C.G. Leung W.K. Potential strategies in the prevention of nonsteroidal anti-inflammatory drugs-associated adverse effects in the lower gastrointestinal tract. Gut Liver 2020 14 2 179 189 10.5009/gnl19201 31547642
    [Google Scholar]
  83. Wu K. Luo Q. Liu Y. Li A. Xia D. Sun X. Causal relationship between gut microbiota and gastrointestinal diseases: A mendelian randomization study. J. Transl. Med. 2024 22 1 92 10.1186/s12967‑024‑04894‑5 38263233
    [Google Scholar]
  84. Singh G. Ramey D. Triadafilopoulos G.G.I. SCORE: A self-assessment instrument to quantify NSAID-related GI complications. Arthritis Rheum Poster Presentation 1998
    [Google Scholar]
  85. Ambegaonkar A. Livengood K. Craig T. Day D. Predicting the risk for gastrointestinal toxicity in patients taking NSAIDs: The gastrointestinal toxicity survey. Adv. Ther. 2004 21 5 288 300 10.1007/BF02850033 15727398
    [Google Scholar]
  86. Jin J. Zhou S. Xu Q. An J. Identification of risk factors in epidemiologic study based on ROC curve and network. Sci. Rep. 2017 7 1 46655 10.1038/srep46655 28436477
    [Google Scholar]
  87. Stern R.H. Why risk factors minimally change the ROC curve AUC. medRxiv 2022 10.1101/2022.02.24.22271481
    [Google Scholar]
  88. White N. Parsons R. Collins G. Barnett A. Evidence of questionable research practices in clinical prediction models. BMC Med. 2023 21 1 339 10.1186/s12916‑023‑03048‑6 37667344
    [Google Scholar]
  89. Cook N.R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007 115 7 928 935 10.1161/CIRCULATIONAHA.106.672402 17309939
    [Google Scholar]
  90. Uno H. Cai T. Pencina M.J. D’Agostino R.B. Wei L.J. On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat. Med. 2011 30 10 1105 1117 10.1002/sim.4154 21484848
    [Google Scholar]
  91. Logan B. ROC Curves and the C statistic. Datum 2013 19
    [Google Scholar]
  92. Rekatsina M. Paladini A. Cifone M.G. Lombardi F. Pergolizzi J.V. Varrassi G. Influence of microbiota on NSAID enteropathy: A systematic review of current knowledge and the role of probiotics. Adv. Ther. 2020 37 5 1933 1945 10.1007/s12325‑020‑01338‑6 32291647
    [Google Scholar]
  93. McEvoy L. Carr D.F. Pirmohamed M. Pharmacogenomics of NSAID-induced upper gastrointestinal toxicity. Front. Pharmacol. 2021 12 684162 10.3389/fphar.2021.684162 34234675
    [Google Scholar]
  94. Miotto R. Wang F. Wang S. Jiang X. Dudley J.T. Deep learning for healthcare: Review, opportunities and challenges. Brief. Bioinform. 2018 19 6 1236 1246 10.1093/bib/bbx044 28481991
    [Google Scholar]
  95. Holzinger A. Langs G. Denk H. Zatloukal K. Müller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdiscip. Rev. Data Min. Knowl. Discov. 2019 9 4 e1312 10.1002/widm.1312 32089788
    [Google Scholar]
  96. Elshennawy N.M. Ibrahim D.M. Sarhan A.M. Arafa M. Deep-risk: Deep learning-based mortality risk predictive models for covid-19. Diagnostics 2022 12 8 1847 10.3390/diagnostics12081847 36010198
    [Google Scholar]
  97. Alzoubi H. Alzubi R. Ramzan N. Deep learning framework for complex disease risk prediction using genomic variations. Sensors 2023 23 9 4439 10.3390/s23094439 37177642
    [Google Scholar]
  98. Zhao X. Wei S. Pan Y. Qu K. Yan G. Wang X. Song Y. Early prognosis prediction for non-variceal upper gastrointestinal bleeding in the intensive care unit: Based on interpretable machine learning. Eur. J. Med. Res. 2024 29 1 442 10.1186/s40001‑024‑02005‑0 39217369
    [Google Scholar]
/content/journals/cds/10.2174/0115748863356598250523095124
Loading
The Impact of Non-Steroidal Anti-Inflammatory Drugs on Gastrointestinal Bleeding: Review on Risk Scoring for Better Prediction
Bentham Science Publishers ; https://doi.org/10.2174/0115748863356598250523095124
/content/journals/cds/10.2174/0115748863356598250523095124
/content/journals/cds/10.2174/0115748863356598250523095124
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: non-Steroidal Anti-Inflammatory Agents ; Adverse Reactions ; risk Factors ; risk Assessment ; gastrointestinal Hemorrhage ; proton pump inhibitors (PPIs) ; cOX-2 inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test